*Celladon trial failure shows field remains high-risk. LONDON, April 27- GlaxoSmithKline is close to seeking European approval for a gene therapy drug to fight the immune deficiency disorder known as "bubble boy" disease, in the latest sign of a renaissance in the technology to fix faulty genes. Gene therapy last year won $3.0 billion of financing, up 510 percent on...» Read More
*Decision marks win for International Stem Cell Corp. BRUSSELS/ LONDON, Dec 18- Europe's top court has opened the door to certain stem cell patents in the European Union by ruling that an organism incapable of developing into a human being is not a human embryo and may be patented. Thursday's judgment by the European Court of Justice was made following a case...
CNBC's Meg Tirrell speaks to Robert Hugin, Celgene chairman & CEO, about exciting new drugs emerging from Celgene's pipeline and the progress being made with Multiple myeloma.
Two stocks you need to watch ahead of San Francisco's 56th ASH hematology conference, with CNBC's Meg Tirrell.
Discussing some of the best stocks in the biotech industry going into 2015, with Michael Yee, RBC Capital Markets.
CNBC's Meg Tirrell provides insight to Biogen Idec's promising early study on its experimental medicine for Alzheimer's disease. Michael Yee, RBC Capital Markets, explains why the stock is headed higher from here.
Biogen's Alzheimer's drug has shown promise in studies, with CNBC's Meg Tirrell.
A Google-backed service to map DNA and identify potential risk factors for some diseases has been launched in the U.K., months after it was banned in the U.S..
Sachin Shah, Analyst at Albert Fried and Company, discusses news that botox maker Allergan agreed to a $66 billion takeover bid from Actavis.
Nov 13- Geron Corp licensed its cancer compound, the last in its pipeline, to a unit of Johnson& Johnson for up to $935 million, sending its shares up as much as 33 percent in extended trading. The license deal comes as a welcome break to the company, which has seen its stock price drop from a high of $71.69 in 2000 to $2.31 on Thursday. If successful, imetelstat would...
Prostate cancer drug developer Dendreon has filed for Chapter 11 bankruptcy protection. CNBC's Meg Tirrell takes a close look at what contributed to the company's downfall.
CNBC's Meg Tirrell speaks to Alex Gorsky, Johnson & Johnson chairman & CEO, about helping military veterans transition from the battlefield into corporate America.
Jack Lief, Arena Pharmaceutical president & CEO, breaks down the company's Q3 earnings and discusses the outlook for its weight loss drug "Belviq."
Russia has a new tech city chock-full of co-working spaces, seed funding, and a research university. All they need now are the technologists.
CNBC's Bertha Coombs takes a close look at the wild swings taking place in the biotech sector.
Matthew Roden, executive director of biotechnology equity research at UBS argued biotech stock valuations are still attractively valued even after their run higher.
Discussing which biotech companies working on treatments for deadly viruses are the most investable, with Dr. Neil Shahrestani, Pura Vida analyst.
The newest batch of crop seeds is setting off another debate over GMOs. This time, they're being blamed for an infestation of "superweeds."
CNBC's Jim Cramer takes a look at what's putting pressure on the markets and why he is watching the biotech sector.
CNBC's Meg Tirrell reports Sam Waksal is back in the biotechnology industry.
Discussing how the Treasury Department's new rules to end tax inversions could impact the pharma deals, with Michael Faerm, Wells Fargo Securities.